USANA HEALTH SCIENCES, INC.
Income Statement
| Line Item | FY2026 | FY2024 | FY2023 | FY2022 | FY2021 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $925.3M | $854.5M | $921.0M | $998.6M | $1.13B | $1.06B | $1.19B | $1.05B |
| Cost of Revenue | $200.9M | $161.2M | $176.7M | $193.9M | $209.1M | $187.5M | $200.7M | $179.4M |
| Gross Profit | $724.4M | $693.3M | $744.3M | $804.7M | $925.5M | $873.4M | $988.5M | $867.9M |
| Gross Margin | 78.3% | 81.1% | 80.8% | 80.6% | 81.6% | 82.3% | 83.1% | 82.9% |
| Operating Expenses | ||||||||
| Research & Development | $10.7M | $11.6M | $11.4M | $11.6M | $10.6M | $10.3M | $10.2M | $9.0M |
| SG&A Expense | $337.4M | $263.3M | $257.0M | $262.3M | $261.2M | $267.7M | $275.1M | $265.1M |
| Operating Income | $37.4M | $66.3M | $93.1M | $107.6M | $176.5M | $146.2M | $188.4M | $132.5M |
| Operating Margin | 4.0% | 7.8% | 10.1% | 10.8% | 15.6% | 13.8% | 15.8% | 12.7% |
| Interest Expense | — | — | $262.0K | $192.0K | $507.0K | $66.0K | $36.0K | $46.0K |
| Pretax Income | $41.5M | $76.4M | $102.5M | $108.6M | $177.9M | $150.5M | $191.5M | $134.6M |
| Income Tax Expense | $30.1M | $34.3M | $38.7M | $39.3M | $53.3M | $50.0M | $65.3M | $72.1M |
| Net Income | $10.8M | $42.0M | $63.8M | $69.4M | $124.7M | $100.5M | $126.2M | $62.5M |
| Net Margin | 1.2% | 4.9% | 6.9% | 6.9% | 11.0% | 9.5% | 10.6% | 6.0% |
| EPS (Basic) | $0.58 | $2.20 | $3.31 | $3.60 | $5.89 | $4.44 | $5.24 | $2.57 |
| EPS (Diluted) | $0.58 | $2.19 | $3.30 | $3.59 | $5.86 | $4.41 | $5.12 | $2.53 |
| Shares Outstanding (Basic) | 18.5M | 19.1M | 19.3M | 19.3M | 21.2M | 22.6M | 24.1M | 24.3M |
| Shares Outstanding (Diluted) | 18.6M | 19.2M | 19.3M | 19.3M | 21.3M | 22.8M | 24.6M | 24.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |